NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









GEMMA Biotherapeutics

GEMMA Biotherapeutics

Private
Philadelphia, PennsylvaniaHealthcare & Life Scienceshttps://www.gemmabiotx.com/

Last Round

Grant

Jul 9, 2026

Total Funding Raised

$34M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

GEMMA Biotherapeutics is a biotechnology company that develops gene therapies for rare diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service, Revenue Share

AI Layer

Non-AI

Keywords

gene therapyadeno-associated virusAAVrare diseasebiotechnologygenetic medicinebiotech startupdrug discoveryclinical stagetherapeutic pipelineprecision medicinedelivery platformbiopharmaclinical trialsintellectual property

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

GEMMA Biotherapeutics Comps

Public and private peers based on sector, stage, and business model.

GEMMA Biotherapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

GEMMA Biotherapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJul 9, 2026
SeedDec 23, 2024
StrategicOct 8, 2024

Key People

Founding team and executive leadership

James M. Wilson

President And Chief Executive Officer

Executive Team

Lori D Kellam

Chief Operating Officer

Executive Team

Juliette Hordeaux

Chief Scientific Officer

Executive Team

Ramon S.

Chief Business Officer

Executive Team

GEMMA Biotherapeutics Investors

Notable investors and investment history

GEMMA Biotherapeutics investors
InvestorRounds
Bioluminescence VenturesSeed
ARPA-HGrant
Earlybird Venture CapitalSeed
Double Point VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 1, 2026

    Affiliation with Franklin Biolabs to translate scientific work into clinical trials.

  • Mar 1, 2026

    Gene therapy pioneer Jim Wilson appointed to lead the company.

GEMMA Biotherapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

GEMMA Biotherapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about GEMMA Biotherapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersPhiladelphia, Pennsylvania
Employee Range63
Year Founded2024
Last FundingJul 9, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.